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Abstract
The revised Surviving Sepsis Campaign (SSC) guidelines for the
management of severe sepsis and septic shock have recently been
published. These guidelines represent the end product of an
intense process and provide a template approach to the early
resuscitation and support of patients with sepsis, based on a
synthesis of evidence that has been shown to improve the outcome
of the septic patient. The SSC guidelines arose from a recognition
that care of the septic patient was suboptimal for at least three
reasons. First, the entity of sepsis was frequently not diagnosed in a
timely fashion, allowing the process to evolve into a life-threatening
syndrome of major physiologic organ system dysfunction. Secondly,
even when sepsis was recognized, the urgency of treatment was
underappreciated – and so haemodynamic resuscitation was
tentative, and the administration of effective antibiotic therapy was
often delayed. Finally, treatment was often suboptimal, and failed to
take advantage of emerging insights into optimal approaches to
patient management. The revised guidelines are far from perfect,
but they represent the best available synthesis of contemporary
knowledge in this area and as such should be promoted.
After a promising conception, a controversial confinement,
and a difficult labour and delivery, the revised Surviving
Sepsis Campaign (SSC) guidelines for the management of
severe sepsis and septic shock have been published [1]. The
guidelines represent the end-product of an intense process
involving 55 intensive care unit experts and 16 scientific
societies (Table 1).
The guidelines process
Guidelines are the product of an explicit, systematic
approach to the evaluation and synthesis of available
information on a particular clinical topic. Their reliability
depends on three factors: the extent to which all relevant
evidence is sought for evaluation; the quality of the available
evidence; and the rigour of the evaluation process used.
The SSC guidelines are based on systematic reviews of
medical literature published since 1980. The guidelines are
clearly selective, being shaped by implicit assumptions about
what questions are considered important. Included studies
were limited to those published in peer-reviewed journals, to
minimize the risk of overinterpreting studies that had not
undergone independent peer review.
A significant challenge to the guidelines process is the
inherent limitations of the available literature. These limitations
are particularly problematic in areas where norms of practice
are well established – the use of antibiotics or source control
for the treatment of infection, for example. Randomized trials
of antibiotics versus placebo in septic shock or of surgical
excision versus expectant therapy for necrotizing soft tissue
infections have not been, and probably never will be,
performed. Recommendations in these areas can therefore
only be informed by expert opinion. Data from studies
undertaken in patient populations other than sepsis patients
(general intensive care unit patients or patients with acute
respiratory distress syndrome, for example) were included if
there was no compelling reason to assume that the
conclusions could not be generalized.
The latest guidelines used the Grading of Recommendations,
Assessment, Development, and Evaluation methodology [2],
which assigns a measure of the strength of the recommen-
dation based not only on the evidence, but also on factors
such as cost, plausibility, toxicity, and clinician acceptance.
This method provides a more nuanced synthesis of data and,
in the current guidelines, the strength of recommendation
was established through a formal voting process, in
recognition of the fact that in many areas participants had
divergent interpretations of the evidence.
The guidelines product
Guidelines are not a compilation of truths, but are a summary
of what is accepted by the authors as the best available
evidence at that time. Recommendations will therefore
change as new information becomes available, and as the
clinical course of the disease of interest alters. Similarly,
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guidelines are not rules and do not preclude the clinician’s
prerogative to make specific decisions in an individual patient
that may be inconsistent with general recommendations. For
example, targeting a specific arterial or central venous
pressure level may not be appropriate for every patient.
Finally, guidelines do not establish legal standards of practice
any more than any other published compilation of data might,
and a strong rating for any particular recommendation does
not preclude further research.
Are the guidelines credible?
Controversy and disagreement is inherent to any human
process of decision-making and consensus-building. The
guidelines development process was explicit and democratic.
Working groups were established in key areas, and
developed specific recommendations following a critical
review and discussion of the literature. Recommendations
that engendered any controversy were submitted to the 55
participants who voted by secret ballot to obtain the final
recommendation; a strong Grading of Recommendations,
Assessment, Development, and Evaluation recommendation
had to receive the support of at least 80% of the participants.
Transparency has always been a key principle of the SSC
guidelines process. All participants’ financial conflicts of
interest have been disclosed in detail. Academic conflicts or
interest arising from having been involved in work driving a
recommendation were addressed by ensuring that working
groups included participants on all sides of an issue, and by
requiring a full vote on contentious questions. Finally, the
industry had no input into the development of the guidelines,
and meetings related to the most recent guidelines received
no industry funding.
Some have argued that the campaign is simply advanced
marketing for activated protein C [3]. That Eli Lilly are interes-
ted in promoting education in the field of sepsis because they
have a product to treat sepsis is unquestionably true. But the
multiple checks and balances outlined above prevent any
direct influence in the guidelines content. While the
consensus process included a number of proponents of
activated protein C, it also included some of activated protein
C’s more vocal critics. If Eli Lilly’s primary objective is to cast
their drug in a favourable commercial light, they have shown
questionable judgement in supporting the SSC, as the
current recommendation for activated protein C use in sepsis
is a weak one.
Sixteen societies have endorsed the guidelines, but two
societies elected not to. The Australia and New Zealand
Intensive Care Society was one of these, concluding that the
guidelines do not represent current practice in Australasia,
and that some of the recommendations are the subject of
ongoing clinical trials. While strongly supporting the
guidelines process, the Society worry that the guidelines
might be used in local quality-improvement programmes,
leading to imposition of practices that are inferior to current
practices.
There is indeed a risk that overly simplistic application of
guidelines may result in less sophisticated management.
Quality-improvement programmes, however, generally seek
evidence of a process rather than compliance with specific
practices. Moreover, the purpose of this and other guidelines
processes has never been to constrain those who provide
exemplary care, but rather to raise global standards by
providing guidance to nonexperts. Initial analyses of data from
centres participating in the campaign do suggest that
guideline compliance can be associated with improved
outcomes [4].
Conclusions
Guidelines are a relatively recent innovation in critical care,
and the SSC has accomplished some remarkable successes,
even before its final efficacy is established. The SSC has
brought together a diverse international group of clinicians,
and has begun to open a creative dialogue between
emergency physicians, intensivists, infectious disease
specialists and surgeons. The campaign has generated
evidence-based recommendations for the early management
of patients with severe sepsis, achieving a measure of
acceptance little short of remarkable. The campaign has
provided momentum to an ongoing collaborative process to
synthesize evidence from clinical trials into practice
Table 1
Evolution of the sepsis guidelines
Organizations Number  of 
involved participants Process Publication
First 1 (ISF) 9a EBM A to E Intensive Care Medicine supplement, 2001
Second 3 (ISF, ESICM, SCCM)b 24 EBM A to E Critical Care Medicine and Intensive Care Medicine, 2004
Third 16 55 GRADE Critical Care Medicine and Intensive Care Medicine, 2008
EBM, evidence-based medicine; ESICM, European Society of Intensive Care Medicine; GRADE, Grading of Recommendations, Assessment,
Development,and Evaluation; ISF, International Sepsis Forum; SCCM, Society of Critical Care Medicine. aActually there were more participants
since there were fellows or junior faculty involved. bA number of other societies also participated.Page 3 of 3
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guidelines. The SSC has not only generated information, but
has embraced a process to disseminate that information, and
to measure the ultimate success of doing so. The campaign
has raised the profile of one of the leading causes of
premature death in the world.
The SSC guidelines were developed to aid the clinician in
managing an enormously complex group of patients. The
guidelines are imperfect, and will change as we learn more.
But the guidelines also represent the best available synthesis
of contemporary knowledge in this area, and for this reason
we believe they must be promoted.
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